AtriCure, Inc. (ATRC)
| Market Cap | 1.46B |
| Revenue (ttm) | 534.53M |
| Net Income (ttm) | -11.45M |
| Shares Out | 50.63M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | 205.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 362,816 |
| Open | 29.20 |
| Previous Close | 29.04 |
| Day's Range | 28.69 - 29.67 |
| 52-Week Range | 27.06 - 43.18 |
| Beta | 1.43 |
| Analysts | Strong Buy |
| Price Target | 51.17 (+77.98%) |
| Earnings Date | May 5, 2026 |
About ATRC
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation Sys... [Read more]
Financial Performance
In 2025, AtriCure's revenue was $534.53 million, an increase of 14.88% compared to the previous year's $465.31 million. Losses were -$11.45 million, -74.39% less than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ATRC stock is "Strong Buy." The 12-month stock price target is $51.17, which is an increase of 77.98% from the latest price.
News
AtriCure to Announce First Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Transcript: The Citizens Life Sciences Conference 2026
Guidance for 2026 projects 12%-14% organic growth, led by pain management and open heart surgery innovations. New product launches, especially in pain management and appendage management, are driving adoption and ASP uplift, while clinical trials like LeAAPS and BoxX-NoAF are set to expand future opportunities.
AtriCure to Participate in the Citizens Life Sciences Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Earnings Call Transcript: Q4 2025
2025 saw 15% revenue growth, margin expansion, and strong cash generation, led by pain management and open ablation. 2026 guidance projects 12–14% growth, with continued innovation, positive cash flow, and margin improvement, despite competitive and reimbursement headwinds.
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Transcript: 44th Annual J.P. Morgan Healthcare Conference
A $10 billion market opportunity is being addressed through innovation in AFib and pain management, with strong global presence and rapid growth in key segments. Clinical trials and new products are set to drive further expansion, while financial performance exceeds guidance and competition is met with ongoing innovation.
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure Transcript: Piper Sandler 37th Annual Healthcare Conference
Flex Mini's rapid adoption and higher ASP drove strong Q3 growth, while Encompass and Box No AF trials are expanding clinical impact. Pain management is growing with cryoSPHERE MAX and XT, and financials show robust EBITDA and margin expansion, targeting mid-teens revenue growth.
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Transcript: Stifel 2025 Healthcare Conference
Significant growth is expected through product innovation, clinical trials, and market expansion, with strong financial performance and operational leverage. New product launches and clinical evidence are set to double the addressable market and drive margin improvement.
AtriCure Transcript: UBS Global Healthcare Conference 2025
Strong Q3 results were driven by new product launches and robust growth in core franchises, with significant runway remaining in open ablation, appendage management, and pain management. Innovation and clinical trials are expected to expand the addressable market, while financial discipline supports margin expansion and sustained growth.
AtriCure Earnings Call Transcript: Q3 2025
Third quarter revenue grew 15.8% year-over-year to $134.3 million, with strong gains in appendage management, open ablation, and pain management. Adjusted EBITDA and cash generation exceeded expectations, prompting raised full-year guidance and continued investment in innovation and clinical trials.
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Participate in Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure to Announce Third Quarter 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Growth accelerated in Q2, driven by new product launches and strong adoption, with innovation and clinical trials expected to expand the addressable market to $10B by 2030. Leadership is maintained through continuous product improvement and robust clinical evidence.
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Transcript: Canaccord Genuity’s 45th Annual Growth Conference
Strong internal innovation and clinical evidence are driving double-digit growth, with new products like cryoSPHERE MAX and AtriClip FLEX-Mini boosting both volume and profitability. Open appendage management is expanding rapidly, while hybrid and minimally invasive segments face headwinds.
AtriCure Earnings Call Transcript: Q2 2025
Q2 2025 revenue rose 17% year-over-year to $136.1M, with strong growth in appendage management and pain management. Adjusted EBITDA more than doubled, and 2025 guidance was raised for both revenue and profitability, despite ongoing hybrid therapy pressures.
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...